NANETS: Despite Dose Reductions, Everolimus Promising in Advanced Pancreatic Neuroendocrine Tumors
Everolimus is a promising treatment option for pancreatic neuroendocrine tumors (pNETs), even though dose reductions are required for most patients.
Everolimus is a promising treatment option for pancreatic neuroendocrine tumors (pNETs), even though dose reductions are required for most patients.
Intraoperatively-placed 5-fluouracil (5-FU) chemotherapy at lymph node surgical dissection beds may lower the chance of necessary surgery.
Pancreatic neuroendocrine tumors (pNETs) harbor genetic mutations in DNA repair pathways that represent “strong candidates”.
Axitinib could be an effective treatment option for unresectable and metastatic carcinoid tumors.
Diarrhea is associated with worse health-related quality of life in patients with neuroendocrine tumor (NET) symptoms.
Epigenetic signatures may help detect and differentiate small intestinal neuroendocrine tumors (SINETs) from other tumor types.
Higher pancreastatin associated with worse survival times in surgically treated small bowel (SBNET) and pancreatic neuroendocrine tumors (PNETs).
Poorly differentiated pancreatic neuroendocrine carcinoma (PNEC) grade 3 tumors demonstrate lower survival after radical resection of PNETs.
Lymph node ratio (LNR) may offer better survival prediction over the current measure for patients with carcinoid neuroendocrine tumors.
Octreotide has demonstrated promising results vs. a subset of carcinoid tumors, despite a lower overall response rate.